Introduction
============

Medulloblastoma (MB) is the most common malignant brain tumor of the pediatric age and a leading cause of cancer related morbidity and mortality ([@B29]). Despite the fact that multimodal aggressive therapy has improved MB outcome, 30% of patients still die of disease and about 40% face tumor recurrence. Moreover, survivors frequently develop long-term severe side effects ([@B39]). In recent years, high-throughput studies have been conducted to better understand MB biology and key signaling pathways that could be addressed to reach a better management of MB patients. These studies allowed the recent WHO 2016 subgrouping of MB ([@B20]), identifying five subgroups: WNT activated, SHH activated P53 wild-type, SHH activated P53 mutant, non-WNT/non-SHH Group 3, non-WNT/non-SHH Group 4 ([@B20]) and more recently 12 molecular subtypes ([@B5]; [@B28]). In this context, SHH subgroups account for about 30% of cases ([@B5]) and they are the most common MB subtypes in infants and adults ([@B16]).

Cancer stem cells (CSCs) have been described in MB ([@B18]; [@B31]; [@B21]; [@B23]). CSCs may arise from the malignant transformation of neural stem cells (NSCs) and represent a reservoir for cancer maintenance and progression ([@B29]). We isolated CSCs from Ptch heterozygous mice, a model of the SHH MB subgroup ([@B12]; [@B31]; [@B41]; [@B35]), and performed transcriptome analysis of both SHH MB CSCs and NSCs isolated from postnatal murine cerebellum for comparison. Among the identified transcripts that characterize SHH MB CSCs, genes involved in the epithelial-mesenchymal transition (EMT) were highly represented and some of them resulted significantly differentially expressed between SHH MB CSCs and NSCs. EMT is characterized by the loss of epithelial characteristics and the acquisition of mesenchymal properties and previous studies linked a shift toward mesenchymal properties to metastatic progression and acquisition of stemness features ([@B38]). Among deregulated markers of EMT in SHH MB CSCs, we focused on Vegfa and Nrp2 that have been described as pivotal players in tumorigenesis and in maintaining stemness and proliferation ([@B34]; [@B7]). We show that both Vegfa and Nrp2 correlate with stemness features in SHH MB CSCs and that Vegfa inhibition determines an increase in the expression of the epithelial marker E-cadherin, a reduction of the mesenchymal marker Vimentin and an impairment of self-renewal. Moreover, since accumulating evidence indicate a crucial role of microRNAs in the regulation of a variety of biological processes, including EMT ([@B22]), we also focused our attention on the microRNAs differentially expressed between NSCs and SHH MB CSCs and involved in EMT identifying an epigenetic circuitry that sustains the mesenchymal phenotype of SHH MB CSCs.

Materials and Methods {#s1}
=====================

Unless otherwise indicated, media and supplements were purchased from Gibco/Invitrogen (Carlsbad, CA) and chemicals from Sigma-Aldrich (St. Louis, MO). Animal experiments were approved by local ethic authorities and conducted in accordance with Italian Governing Law (D.lgs 26/2014; Prot. no. 03/2013).

Cell Culture, Treatments, Proliferation and Oncosphere-Forming Assays
---------------------------------------------------------------------

SHH MB CSCs were derived from spontaneous tumours arisen in Ptch1 + /− mice and maintained as previously described ([@B31]). To induce differentiation, cells were plated on D-poly-lysine coated supports and treated for 48 h with 2 μM retinoic acid ([@B35]). BrdU incorporation was used to evaluate SHH MB CSCs proliferation before (CSC) and after differentiation (CSC-diff) ([@B24]). Pharmacological inhibition of Vegfa was induced by treating SHH MB CSC cells for 72 h with 10, 20, 40 and 60 ng/ml anti-Vegf (MAB 293, R&D Systems). Synthetic miR-466f-3p (4464066, Thermo Fisher Scientific) or negative control (miRIDIAN CN-001000-01; Dharmacon) were used as previously described ([@B4]). Cell proliferation was evaluated by trypan blue exclusion assay ([@B4]). Oncosphere-forming assay of SHH MB CSC was performed as previously described ([@B31]). Unpaired *t*-test of three independent experiments was performed using GraphPad Prism Software version 6.0 (CA, United States), *p*--values \< 0.05 were considered statistically significant.

RNA Extraction, miRNA and mRNA Sequencing
-----------------------------------------

Three biological replicates of SHH MB CSCs were subjected to miRNA-sequencing or mRNA sequencing, quality control, mapping, quantification and differential expression analysis was performed between SHH MB CSCs and NSCs ([@B2]; [@B30]).

Immunofluorescence
------------------

Immunofluorescence studies were performed according to standard procedures ([@B3]) using the following primary antibodies: anti-Vegfa Clone VG1 (05-1117, Millipore), anti-Nrp2 H-300 (sc-5542), anti-Nanog (8600S, Cell Signaling), anti-NeuN (MAB377, Millipore).

Immunochemical Analysis
-----------------------

Western blotting was performed as previously described ([@B25]) using the following primary antibodies: anti-E-cadherin (610181, BD Biosciences), anti-Vimentin (92547, Abcam), anti-Vegfa Clone VG1 (05-1117, Millipore), anti-Nrp2 (ab 185710, Abcam), anti-β-actin I-19 (sc-1616, Santa Cruz).

Results
=======

EMT Related Transcripts Characterize SHH MB CSC
-----------------------------------------------

We recently conducted small RNA and trascriptome sequencing on SHH MB CSCs and NSCs ([@B2]; [@B30]). In this study, we focused on the EMT related RNAs that characterize SHH MB CSCs compared to NSCs, querying the differentially expressed transcripts listed in the EMT gene database dbEMT ([@B42]). Deregulated transcripts are shown in Figure [1](#F1){ref-type="fig"}, specifically, 17 mRNA resulted down-regulated and 15 up-regulated in SHH MB CSCs when compared with NSCs (Figures [1A,B](#F1){ref-type="fig"}). Since we were interested in the mechanisms that could regulate EMT in SHH MB CSCs, we used qPCR to validate the up-regulated transcripts (data not shown). Among them, we focused on Nrp2 and Vegfa, whose role in maintaining stemness and proliferation in lung cancer stem cells we recently demonstrated ([@B32]). To investigate whether they correlate with stemness features in the context of SHH MB, the protein expression of Vegfa and Nrp2 in SHH MB CSCs was evaluated before (CSC) and after differentiation (CSC-diff). Differentiated cells are characterized by a lower proliferative rate, as shown by the reduction in BrdU incorporation (Figure [1C](#F1){ref-type="fig"}), and less aggressive behavior in comparison with SHH MB CSCs ([@B26]). We observed a reduction in the protein level of Vegfa and Nrp2 in SHH MB CSC after 48h of Retinoic Acid (RA)-induced differentiation (Figures [1D,E](#F1){ref-type="fig"}). The differentiated status of SHH MB CSCs was confirmed by the decrease of the stemness marker Nanog and the increase of the neuronal marker NeuN ([@B33]) after differentiation (Figure [1E](#F1){ref-type="fig"}).

![EMT-related characterization of SHH MB CSC. **(A,B)** Statistically significant up-regulated **(A)** and down-regulated **(B)** EMT-related genes in SHH MB CSC vs. NSC. **(C)** Bromodeoxyuridine (BrdU) uptake in SHH MB CSC before (CSC) and after differentiation (CSC-diff). ^∗∗^ indicates *p* \< 0.01 vs. CSC-diff. **(D,E)** Immunofluorescence staining of the stemness marker Nanog and the neuronal marker NeuN, and of the EMT-related markers, Vegfa and Nrp2, in SHH MB CSC before **(D)** and after 48 h differentiation with 2 μM RA **(E)**. SHH MB CSCs express higher levels of Vegfa and Nrp2 than SHH MB CSC-diff. The differentiated status of SHH MB CSC was confirmed by the down-regulation of Nanog and the up-regulation of NeuN in SHH MB CSC after 48 h of differentiation. Bars, 10 μm.](fphar-09-01281-g001){#F1}

EMT-Related Circuitry Activation in SHH MB CSCs
-----------------------------------------------

To unravel the role of Vegfa in SHH MB CSCs, we performed pharmacological modulation by using a blocking antibody. We focused on Vegfa since it acts as a ligand for Nrp2, therefore its inhibition likely determines an inhibition of the Nrp2-mediated signaling. After 72h, Vegfa inhibition induced an impairment of both cell proliferation (Figure [2A](#F2){ref-type="fig"}) and clonogenic ability (Figure [2B](#F2){ref-type="fig"}) of SHH MB CSCs. Concordantly, we observed an increase in the epithelial marker E-cadherin and a reduction in the mesenchymal marker Vimentin (Figure [2C](#F2){ref-type="fig"}), indicating that Vegfa is involved in the induction of EMT in SHH MB CSCs. Subsequently, we investigated an EMT-related network involving both mRNAs and microRNAs that could characterize SHH MB CSCs. With this aim, we compared the miRnome of SHH MB CSC and NSC ([@B2]) focusing on the differentially expressed microRNAs that target the previously identified deregulated transcripts (Figures [1A,B](#F1){ref-type="fig"}) as reported in miRTarBase ([@B6]). Specifically, we observed six down-regulated and three up-regulated microRNAs in SHH MB CSCs (Figure [2D](#F2){ref-type="fig"}), that we validated by using qPCR (data not shown). Among them, miR-106a targeted only Vegfa, while miR-3082 and miR-5122 targeted only Nrp2. Interestingly, miR-466f-3p targeted both Vegfa and Nrp2. To confirm the regulation of Vegfa and Nrp2 by miR-466f-3p in SHH MB CSCs, we overexpressed this microRNA obtaining a reduction of Vegfa and Nrp2 levels (Figure [2E](#F2){ref-type="fig"}). These results indicate the existence of a functional circuitry between these molecules (Figure [2F](#F2){ref-type="fig"}) involved in the induction of EMT in SHH MB CSCs.

![Pharmacologic inhibition of Vegfa signaling and EMT-related microRNA/mRNA network in SHH MB CSC. **(A--C)** After 72 h of Vegfa inhibition cell proliferation **(A)** and self-renewal **(B)** were impaired. Western blot analysis was performed with the more effective anti-Vegfa concentration (60 ng/mL) and showed an increase in the expression of the epithelial marker E-cadherin and a reduction in the level of the mesenchymal marker Vimentin in respect to untreated SHH MB CSC (Ctrl) **(C)**. ^∗^ indicates *p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001, and ^∗∗∗∗^*p* \< 0.0001 vs. Ctrl **(D)** Statistically significant deregulated EMT-related microRNAs in SHH MB CSC vs. NSC that target the previously identified deregulated transcripts. **(E)** Western blot analysis was performed after over-expression of 20 nM of miR-466f-3p for 48 h and demonstrated a reduction of Vegfa and Nrp2 expression in respect to untreated SHH MB CSCs (Ctrl) **(F)** The miR-466f-3p/Vegfa/Nrp2 circuitry sustaining the mesenchymal phenotype of SHH MB CSC.](fphar-09-01281-g002){#F2}

Discussion
==========

MB is the most frequent malignant childhood brain tumor and CSCs have been an important focus for researchers. On the basis of the cancer stem cell hypothesis, CSCs represent a subset of cells within the tumor with the ability to proliferate and maintain tumor growth ([@B21]). CSCs have been identified in all MB subtypes and are responsible for therapeutic resistance and invasion ([@B17]). The cellular origin and stage of differentiation are of pivotal importance in determining the tumor phenotype in MB ([@B19]). Specifically, in SHH MB the deregulated SHH signaling works as a potent mitogen to induce the proliferation of the granule neuron precursors, where a specific deletion of Ptch1 or Smo activation determines MB in mouse models ([@B36]). Some reports described the importance of EMT in increasing the migratory and invasive abilities of MB cells ([@B1]; [@B13]; [@B37]; [@B8]; [@B9]), however, no report has addressed the EMT phenomenon in MB CSCs. Since CSCs represent interesting candidates to determine MB migration and invasion, we examined the role of EMT in CSCs belonging to a SHH MB model, derived from specific transgenic mice haploinsufficient for Ptch1 (Ptch1 + /−).

Firstly, we evaluated the expression of EMT-related genes in SHH MB CSC in comparison with NSC cells derived from postnatal cerebellum, where medulloblastoma arises.

Among the 15 up-regulated EMT-related transcripts we focused on Vegfa, which is one of the main mammalian HH target genes ([@B17]), and Nrp2, a transmembrane protein required for HH signal transduction ([@B10]). Vegfa has been described in solid cancers as a crucial determinant of the increase in tumorigenicity of cells that undergo EMT, both inducing angiogenetic ([@B7]) and non-angiogenetic events ([@B11]). Moreover, Vegfa has been demonstrated to increase the tumor-initiating stem cell population, to induce EMT and metastasis ([@B15]), suggesting a strong link between CSC and EMT. On this basis, we inhibited Vegfa and evaluated the proliferative and self-renewal ability of CSCs and the modulation of two critical markers of the EMT process. Vegfa inhibition induced a reduction in cell growth and clonogenic ability of CSCs and an up-regulation of the cell adhesion molecule E-cadherin, paralleled by a down-regulation of the mesenchymal marker, Vimentin. These results indicate that Vegfa is involved both in maintaining the stem cells niche and in promoting cancer invasion and metastasis by controlling the EMT program. Also Nrp2 is involved in EMT and has been reported as up-regulated both in hepatocellular carcinoma and in lung cancer cells after EMT induction by TGF-β1 ([@B27]; [@B40]). Nrp2 inhibition in a cellular mouse model of SHH MB decreased tumor growth both *in vitro* and *in vivo* and the consequent mortality ([@B10]). Since the importance of microRNAs has been well documented in cancers and we were interested in the identification of possible networks connecting Vegfa and/or Nrp2 with the EMT phenomenon in SHH MB CSC, we extended the analysis to the EMT related microRNAs deregulated between SHH MB CSC and NSC. Interestingly we identified a microRNA, miR-466f-3p, that targeted both Vegfa and Nrp2. Knowledge about this microRNA is scarce and scant. In 2011 Zheng demonstrated that the miR-466 group is contained in the intron of *Sfmbt2* ([@B43]), while in 2012 Hunsberger et al. showed an increase in miR-466f expression in a rat model of middle cerebral artery occlusion ([@B14]). The low level of miR-466f-3p in SHH MB CSCs is involved in the more mesenchymal phenotype of these cells in respect to NSCs. In fact the down-regulation of miR-466f-3p is related with an increase of the Nrp2 level or of its ligand, Vegfa, with a consequent increase in Nrp2 activation. In both cases the final result sustains the mesenchymal phenotype of SHH MB CSCs. In summary, our study provides novel evidence of an epigenetic mechanism that sustains EMT related genes in SHH MB CSC, however, future investigations and additional studies are needed to better clarify the role of the miR-466f-3p/Vegfa/Nrp2 circuitry.
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